117 related articles for article (PubMed ID: 10930855)
1. [Activated protein C resistance and cardiolipin antibodies in leg ulcers].
Maréchal V; De Maistre E; Barbaud A; Albuisson E; Lecompte T; Gobert B; Bene M; Faure G; Schmutz J
Ann Dermatol Venereol; 2000; 127(6-7):585-9. PubMed ID: 10930855
[TBL] [Abstract][Full Text] [Related]
2. Activated protein C resistance and anticardiolipin antibodies in patients with venous leg ulcers.
Grossman D; Heald PW; Wang C; Rinder HM
J Am Acad Dermatol; 1997 Sep; 37(3 Pt 1):409-13. PubMed ID: 9308555
[TBL] [Abstract][Full Text] [Related]
3. A prospective coagulation study including resistance to activated protein C and mutations in factors V and II in venous leg ulcers.
Ribeaudeau F; Senet P; Cayuela JM; Fund X; Paul C; Robert C; Scrobohaci ML; Dubertret L
Br J Dermatol; 1999 Aug; 141(2):259-63. PubMed ID: 10468797
[TBL] [Abstract][Full Text] [Related]
4. [Leg ulcers and antiphospholipid antibodies. Prospective study of 48 cases].
Alcaraz I; Lefevre I; Wiart T; Lafon C; Forzy G; Modiano P
Ann Dermatol Venereol; 1999 Apr; 126(4):313-6. PubMed ID: 10421932
[TBL] [Abstract][Full Text] [Related]
5. Resistance to activated protein C due to factor V Leiden mutation: high prevalence in patients with post-thrombotic leg ulcers.
Gaber Y; Siemens HJ; Schmeller W
Br J Dermatol; 2001 Mar; 144(3):546-8. PubMed ID: 11260012
[TBL] [Abstract][Full Text] [Related]
6. [Anticardiolipin antibodies in leg ulcers].
Skare TL; Ribas CA; Malafaia O; Ribas Filho JM; Nassif PA; Nascimento MM; Fonseca VR
Rev Col Bras Cir; 2009 Apr; 36(2):152-6. PubMed ID: 20076888
[TBL] [Abstract][Full Text] [Related]
7. Antiphospholipid antibodies and thrombosis: association with acquired activated protein C resistance in venous thrombosis and with hyperhomocysteinemia in arterial thrombosis.
Kassis J; Neville C; Rauch J; Busque L; Chang ER; Joseph L; Le Comte M; Subang R; Fortin PR
Thromb Haemost; 2004 Dec; 92(6):1312-9. PubMed ID: 15583739
[TBL] [Abstract][Full Text] [Related]
8. Coagulation studies, factor V Leiden, and anticardiolipin antibodies in 40 cases of cerebral venous thrombosis.
Deschiens MA; Conard J; Horellou MH; Ameri A; Preter M; Chedru F; Samama MM; Bousser MG
Stroke; 1996 Oct; 27(10):1724-30. PubMed ID: 8841318
[TBL] [Abstract][Full Text] [Related]
9. [Platelet count and clinical profile of anticardiolipin positive leg ulcers].
Skare TL; Ribas CA; Malafaia O; Ribas Filho JM; Nassif PA; Nascimento MM; Pachnicki JP
Rev Col Bras Cir; 2009 Oct; 36(5):420-4. PubMed ID: 20069154
[TBL] [Abstract][Full Text] [Related]
10. Activated protein C resistance and lupus anticoagulant activity induced by plasma and purified monospecific human IgG anti-beta2-glycoprotein-I antibodies.
Viveros ME; Cabiedes J; Reyes E; Cabral AR
Rev Invest Clin; 2005; 57(4):563-71. PubMed ID: 16315641
[TBL] [Abstract][Full Text] [Related]
11. [Increased prevalence of APC-resistance (factor V Leiden mutation) in patients with postthrombotic syndrome].
Gaber Y; Siemens HJ; Schmeller W
Hautarzt; 2000 Aug; 51(8):590-2. PubMed ID: 10997314
[TBL] [Abstract][Full Text] [Related]
12. No excess of factor V:Q506 genotype but high prevalence of anticardiolipin antibodies without antiendothelial cell antibodies in retinal vein occlusion in young patients.
Scott JA; Arnold JJ; Currie JM; Broadfoot C; Davidson M; Kelly KF; Graham A; Kirkpatrick JN; Greaves M
Ophthalmologica; 2001; 215(3):217-21. PubMed ID: 11340395
[TBL] [Abstract][Full Text] [Related]
13. Activated protein C resistance and anticardiolipin antibodies in patients with venous leg ulcers.
Fisher DA
J Am Acad Dermatol; 1998 Aug; 39(2 Pt 1):299-300. PubMed ID: 9704858
[No Abstract] [Full Text] [Related]
14. Frequent occurrence of anticardiolipin antibodies, Factor V Leiden mutation, and perturbed endothelial function in chronic myeloproliferative disorders.
Jensen MK; de Nully Brown P; Thorsen S; Hasselbalch HC
Am J Hematol; 2002 Mar; 69(3):185-91. PubMed ID: 11891805
[TBL] [Abstract][Full Text] [Related]
15. Leg ulcers associated with factor V Leiden and prothrombin G20210A and methyltetrahydrofolate reductase mutations: successful treatment with warfarin.
Clivati Brandt HR; de Lorenzo Messina MC; Belda Júnior W; Costa Martins JE; Criado PR
Int J Dermatol; 2007 Dec; 46(12):1319-20. PubMed ID: 18173539
[No Abstract] [Full Text] [Related]
16. The prevalence of factor V Leiden mutation in patients with leg ulcers and venous insufficiency.
Maessen-Visch MB; Hamulyak K; Tazelaar DJ; Crombag NH; Neumann HA
Arch Dermatol; 1999 Jan; 135(1):41-4. PubMed ID: 9923779
[TBL] [Abstract][Full Text] [Related]
17. Activated protein C resistance caused by factor V gene mutation: common coagulation defect in chronic venous leg ulcers?
Peus D; Heit JA; Pittelkow MR
J Am Acad Dermatol; 1997 Apr; 36(4):616-20. PubMed ID: 9092749
[TBL] [Abstract][Full Text] [Related]
18. Differential diagnosis of leg ulcers.
Pannier F; Rabe E
Phlebology; 2013 Mar; 28 Suppl 1():55-60. PubMed ID: 23482536
[TBL] [Abstract][Full Text] [Related]
19. Anticardiolipin antibodies and lower leg plaques and ulcers of 45 years duration.
Bissonnette R; Tousignant J
Int J Dermatol; 1993 Aug; 32(8):619. PubMed ID: 8407085
[No Abstract] [Full Text] [Related]
20. Clinical evaluation of a functional prothrombin time-based assay for identification of factor V Leiden carriers in a group of Italian patients with venous thrombosis.
Gessoni G; Valverde S
Blood Coagul Fibrinolysis; 2007 Oct; 18(7):603-10. PubMed ID: 17890946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
